Toll Free: 1-888-928-9744

Nabriva Therapeutics AG - Product Pipeline Review - 2014

Published: Dec, 2014 | Pages: 26 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Nabriva Therapeutics AG - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Nabriva Therapeutics AG - Product Pipeline Review - 2014', provides an overview of the Nabriva Therapeutics AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nabriva Therapeutics AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Nabriva Therapeutics AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Nabriva Therapeutics AG's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Nabriva Therapeutics AG's pipeline products

Reasons to buy

- Evaluate Nabriva Therapeutics AG's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Nabriva Therapeutics AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Nabriva Therapeutics AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Nabriva Therapeutics AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nabriva Therapeutics AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Nabriva Therapeutics AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Nabriva Therapeutics AG Snapshot 4
Nabriva Therapeutics AG Overview 4
Key Information 4
Key Facts 4
Nabriva Therapeutics AG - Research and Development Overview 5
Key Therapeutic Areas 5
Nabriva Therapeutics AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Nabriva Therapeutics AG - Pipeline Products Glance 10
Nabriva Therapeutics AG - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Nabriva Therapeutics AG - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Nabriva Therapeutics AG - Drug Profiles 13
BC-3781 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
BC-7013 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Small Molecules to Inhibit 23S Ribosomal RNA for Infections 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Nabriva Therapeutics AG - Pipeline Analysis 17
Nabriva Therapeutics AG - Pipeline Products by Target 17
Nabriva Therapeutics AG - Pipeline Products by Route of Administration 18
Nabriva Therapeutics AG - Pipeline Products by Molecule Type 19
Nabriva Therapeutics AG - Pipeline Products by Mechanism of Action 20
Nabriva Therapeutics AG - Recent Pipeline Updates 21
Nabriva Therapeutics AG - Dormant Projects 23
Nabriva Therapeutics AG - Locations And Subsidiaries 24
Head Office 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 26
Disclaimer 26
List of Tables
Nabriva Therapeutics AG, Key Information 4
Nabriva Therapeutics AG, Key Facts 4
Nabriva Therapeutics AG - Pipeline by Indication, 2014 7
Nabriva Therapeutics AG - Pipeline by Stage of Development, 2014 8
Nabriva Therapeutics AG - Monotherapy Products in Pipeline, 2014 9
Nabriva Therapeutics AG - Phase II, 2014 10
Nabriva Therapeutics AG - Phase I, 2014 11
Nabriva Therapeutics AG - Preclinical, 2014 12
Nabriva Therapeutics AG - Pipeline by Target, 2014 17
Nabriva Therapeutics AG - Pipeline by Route of Administration, 2014 18
Nabriva Therapeutics AG - Pipeline by Molecule Type, 2014 19
Nabriva Therapeutics AG - Pipeline Products by Mechanism of Action, 2014 20
Nabriva Therapeutics AG - Recent Pipeline Updates, 2014 21
Nabriva Therapeutics AG - Dormant Developmental Projects,2014 23 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify